Kwality Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Kwality Pharmaceuticals Ltd filed with BSE on 12 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Kwality Pharmaceuticals reported oncology revenue of INR30-35 crores for the quarter and reiterated a full-year FY27 revenue target of over INR700 crores with EBITDA margins between 26% to 27%. Management discussed registration progress across the general facility, oncology, biological and hormone units, and addressed debtor days, capex plans, and a proposed change of statutory auditor to KPMG. The company also detailed longer-term revenue expectations from its hormone, biosimilar and Erythropoietin programs extending to FY29 and FY30.
Numbers mentioned
Total sales revenue: plus INR700 crores (FY27)
p. 3
“Our total sales revenue expected in FY27 will be plus INR700 crores, and with EBITDA margins between 26% to 27%.”
Aditya Arora, page 3 of the filed PDF · View the filing
Gross margin: 53% (Q1 FY27)
p. 10
“It is now 53%.”
Aditya Arora, page 10 of the filed PDF · View the filing
Gross margin: 56% or 57% (Q4 FY26)
p. 10
“Actually, the last quarter the gross margins were roughly around 56% or 57%.”
Aditya Arora, page 10 of the filed PDF · View the filing
Oncology revenue: INR30 crores to INR35 crores (Q1 FY27)
p. 16
“So, we did INR30 crores -- INR30 crores to INR35 crores in -- I think in this quarter sir.”
Aditya Arora, page 16 of the filed PDF · View the filing
Debtor days: 165 days to 170 days (Current)
p. 11
“So receivables will be, sir, roughly around 165 days to 170 days now.”
Aditya Arora, page 11 of the filed PDF · View the filing
Debtor days: 208 days (FY26)
p. 9
“So this will be from 208 days it will come down to 165 days, 170 days considering the payment cycle from the specifically from the MENA region and CIS region and GCC part, it is now improving.”
Aditya Arora, page 9 of the filed PDF · View the filing
Total capex: INR185 crores, INR190 crores
p. 11
“So we are looking at overall INR185 crores, INR190 crores capex.”
Aditya Arora, page 11 of the filed PDF · View the filing
Domestic API procurement: 80% to 85%
p. 11
“So sir, 80% to 85% of the total procurement of Kwality is from the domestic API, and only 15% is from China.”
Aditya Arora, page 11 of the filed PDF · View the filing
General facility capacity utilization: 75% to 80%
p. 15
“Ma'am, the general facility I think by 75% to 80% has already been utilized and the oncology also the existing facility is again 75% to 80% utilized.”
Aditya Arora, page 15 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Oncology mix — 25% to 30% · FY27
stated conditionally by Aditya Arora
p. 3
“Okay sir. Firstly, oncology will be roughly between 25% to 30% considering the timelines for getting the oncology registrations will be, getting a little delayed.”
Aditya Arora, page 3 of the filed PDF · View the filing
Erythropoietin domestic sales — before calendar year 2027 end
stated firmly by Aditya Arora
p. 4
“So we are likely to commence the Erythropoietin sales in the domestic and international market before end of calendar year '27.”
Aditya Arora, page 4 of the filed PDF · View the filing
Revenue — INR1,500 crores · by 2030
stated as an aspiration by Aditya Arora
p. 6
“I think we have developed a revenue model wherein we believe by 2030 we can easily reach INR1,500 crores revenue mark.”
Aditya Arora, page 6 of the filed PDF · View the filing
Revenue growth rate — 25% to 30% · FY28 onwards
stated as an aspiration by Aditya Arora
p. 6
“So we will see a year-on-year growth of 25% to 30%.”
Aditya Arora, page 6 of the filed PDF · View the filing
EBITDA margin — 29% to 30% · at INR1,000 crores revenue
stated conditionally by Aditya Arora
p. 6
“So probably at INR1,000 crores revenue, you will see a 29% to 30% EBITDA margins.”
Aditya Arora, page 6 of the filed PDF · View the filing
Revenue — INR700 crores or INR720 crores · FY27
stated firmly by Aditya Arora
p. 6
“But this financial year, we do believe that 100% the sales will cross the INR700 crores or INR720 crores mark.”
Aditya Arora, page 6 of the filed PDF · View the filing
Hormone facility revenue — INR70 crores to INR80 crores · FY28
stated conditionally by Aditya Arora
p. 8
“So that, you can say, a INR70 crores to INR80 crores revenue we can generate in FY28.”
Aditya Arora, page 8 of the filed PDF · View the filing
Hormone facility revenue — INR200 crores · FY29
stated conditionally by Aditya Arora
p. 8
“But for Kwality to get the COPPs and complete with the bioequivalent studies of various oral solid and injectable products of hormone, I think by FY29 we can generate a INR200 crores revenue.”
Aditya Arora, page 8 of the filed PDF · View the filing
GMP certificate approval — June or July
stated conditionally by Aditya Arora
p. 8
“So probably in June or July you will expect the GMP.”
Aditya Arora, page 8 of the filed PDF · View the filing
BE program revenue — INR80 crores to INR100 crores · next year
stated conditionally by Aditya Arora
p. 8
“So next year you can expect at least INR80 crores to INR100 crores revenue from the BE program.”
Aditya Arora, page 8 of the filed PDF · View the filing
BE program revenue — INR400 crores or INR500 crores · FY29
stated conditionally by Aditya Arora
p. 9
“But FY29 will be an immediate jump to at least INR400 crores or INR500 crores revenue.”
Aditya Arora, page 9 of the filed PDF · View the filing
Keytruda commercialization — before end of calendar year 2028
stated conditionally by Aditya Arora
p. 9
“So before end of calendar year '28, we think we will be able to commercialize this product, considering that end of calendar year '28 the patent is going to get expired.”
Aditya Arora, page 9 of the filed PDF · View the filing
Debtor days — 155 days to 160 days
stated as an aspiration by Aditya Arora
p. 9
“I think the debtor days will come down to 165 days or 170 days, but we are trying that in our regular operations, it should be roughly around 155 days to 160 days.”
Aditya Arora, page 9 of the filed PDF · View the filing
Gross margin — 49% to 51% · at INR700 crores-plus revenue
stated conditionally by Aditya Arora
p. 10
“So probably I think at when the revenues are INR700 crores or INR700-plus crores, it should be between 49% to 51%.”
Aditya Arora, page 10 of the filed PDF · View the filing
Gross margin — 47%
stated as an aspiration by Aditya Arora
p. 10
“And ideally, it should be considering the BE program and the BE products, along with the niche injectable registrations, it should come down to 47%.”
Aditya Arora, page 10 of the filed PDF · View the filing
KPMG auditor appointment — Q3 or Q4 of FY27
stated firmly by Aditya Arora
p. 6
“Most probably it is planned for the quarter three or quarter four.”
Aditya Arora, page 6 of the filed PDF · View the filing
Erythropoietin revenue (Unit 5) — INR200 crores to INR250 crores · FY30
stated conditionally by Aditya Arora
p. 14
“So, you're saying, so firstly, FY30, INR250 crores without Pembrolizumab, Keytruda, INR200 crores to INR250 crores is 100% achievable, sir.”
Aditya Arora, page 14 of the filed PDF · View the filing
Hormone facility revenue (Unit 6) — INR200 crores to INR250 crores · FY30
stated conditionally by Aditya Arora
p. 14
“Then, coming to the hormone facility, by FY30, yes, INR200 crores to INR250 crores you can take into consideration.”
Aditya Arora, page 14 of the filed PDF · View the filing
Oncology revenue — INR100 crores, INR110 crores · FY27
stated conditionally by Aditya Arora
p. 17
“So, probably INR100 crores, INR110 crores will be, you know, achieved from oncology.”
Aditya Arora, page 17 of the filed PDF · View the filing
Total revenue — INR700 crores plus · FY27
stated firmly by Aditya Arora
p. 17
“No. So, our, you know, target for this year has been revised to INR700 crores plus revenue.”
Aditya Arora, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said oncology registrations are delayed and expected in Q4 FY27, while general facility registrations from MENA and LATAM boosted revenue this quarter.
Answered by Aditya Arora
Asked by Aryan Mehta: Why did oncology mix decline to 20% and is the company still guiding for 30% oncology share?
p. 3
“This quarter, in this last two quarters, we got multiple registrations from the general facilities, from MENA region and the LATAM region.”
Aditya Arora, page 3 of the filed PDF · View the filing
Management said there was no regulatory risk given repeated successful audits and inspections, but cautioned internally against complacency.
Answered by Aditya Arora
Asked by Utkarsh Somaiya: Are there risks management is trying to mitigate?
p. 6
“We already had like risk-based investigations from CDSCO seven times almost now in last three years. So neither of these investigations where there was any issue.”
Aditya Arora, page 6 of the filed PDF · View the filing
Management pointed to the ability to replicate reference product formulations as the key differentiator.
Answered by Aditya Arora
Asked by Nirali Shah: What is Kwality's strongest competitive moat - formulation know-how, manufacturing, regulatory approvals or customer relationships?
p. 10
“I think the ability to, imitate the correct formulation of the reference product is one ability.”
Aditya Arora, page 10 of the filed PDF · View the filing
Management said margins improved sequentially from the prior quarter and attributed lower margins to the high share of ROW market revenue.
Answered by Aditya Arora
Asked by Abhijeet: What explains the gross margin contraction year-on-year?
p. 10
“But it is going to improve, it is going to improve on each quarter.”
Aditya Arora, page 10 of the filed PDF · View the filing
Management clarified the 500 liter unit is physically installed but still awaiting CDSCO approval, with current operations at 100 liter capacity.
Answered by Aditya Arora
Asked by Manan: Is the 500 liter bioreactor expansion completed or still pending?
p. 12
“So, basically, right now we got the CDSCO approval for 100 liter only, sir. 500 liter, we didn't, it is already installed and it will be 5 times the capacity.”
Aditya Arora, page 12 of the filed PDF · View the filing
Management confirmed KPMG will be appointed via an EGM by Q3 FY27.
Answered by Aditya Arora
Asked by Kunal Dube: Is KPMG confirmed to become statutory auditor and by when?
p. 16
“KPMG will be appointed.”
Aditya Arora, page 16 of the filed PDF · View the filing
Management said these segments are still going through clinical trials and registrations, so their contribution was pushed to FY30 estimates.
Answered by Aditya Arora
Asked by Saurabh Gupta: Why are biological and hormone revenues excluded from the current guidance?
p. 18
“So, one will be commercialized from next financial year, sir, hormone facility. And biological because since a lot of things are going in clinical trials, so we have taken these two into the major consideration in FY30, not in FY29.”
Aditya Arora, page 18 of the filed PDF · View the filing
Risks flagged
Regulatory delays from health ministries in various countries could affect sales targets
p. 6
“Again, there are certain things which are in control of the Ministry of Health of various countries. So sometimes there is a delay which might affect the sales targets what we have given.”
Aditya Arora, page 6 of the filed PDF · View the filing
Directors becoming complacent with small successes
p. 7
“It is now very important that the directors, they should not get carried away with small successes.”
Aditya Arora, page 7 of the filed PDF · View the filing
Delay in BE studies and registrations could limit hormone facility revenue growth
p. 15
“Sir, see basically if we are -- if the buy equivalences and the registration do not happen on time, then the revenues will be INR60 crores-INR70 crores depending upon what tenders we win, what ROW market we are able to get immediate sales.”
Aditya Arora, page 15 of the filed PDF · View the filing
Uncertainty over future biosimilar market pricing and competition affecting margin visibility
p. 13
“But we have not -- we have not taken -- you know, we do not know how many players are going to enter the biological market and what is going to be the -- I mean the price of the product.”
Aditya Arora, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.